Standout Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high... 2017 2026 2020 2023 1.9k
  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (2017)
    Michael J. Overman, Ray McDermott et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 6 from Science/Nature 70 standout
Sub-graph 1 of 22

Citing Papers

Polymeric Nanoparticles for Drug Delivery
2024 Standout
In situ targeted base editing of bacteria in the mouse gut
2024 StandoutNature
2 intermediate papers

Works of Michael D. Axelson being referenced

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
2013

Author Peers

Author Last Decade Papers Cites
Michael D. Axelson 374 1808 795 432 6 2.2k
Michael A. Morse 287 1712 630 449 22 2.1k
Ka Yeung Mark Wong 209 1612 753 335 17 1.8k
Pamela K. McAllister 446 1672 758 119 14 2.3k
Daniel Byrom 1114 2043 403 822 5 2.9k
Leigh Marcus 267 1020 340 204 16 1.5k
S Hellman 447 796 356 275 23 1.9k
Deepika Cattry 277 2144 890 1224 4 2.6k
Alice Pons 406 2381 214 1294 8 2.8k
Davide Zecchin 1341 1331 485 252 13 2.3k
Antonina V. Kurtova 1163 1019 458 597 20 2.5k

All Works

Loading papers...

Rankless by CCL
2026